2. Search Result
Search Result
Results for "

BALB cA Jcl-nu

" in MedChemExpress (MCE) Product Catalog:

969

Inhibitors & Agonists

4

Screening Libraries

26

Fluorescent Dye

21

Biochemical Assay Reagents

101

Peptides

2

Inhibitory Antibodies

119

Natural
Products

80

Recombinant Proteins

64

Isotope-Labeled Compounds

21

Antibodies

4

Click Chemistry

26

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15044
    NU1025

    		PARP Neurological Disease Cancer
    NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity .
    NU1025
  • HY-110127
    NU9056
    5 Publications Verification

    		 Histone Acetyltransferase Apoptosis Cancer
    NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells .
    NU9056
  • HY-18930
    NU6300

    		CDK Cancer
    NU6300 is a covalent, irreversible and ATP-competitive CDK2 inhibitor with an IC50 value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related .
    NU6300
  • HY-13816
    NU6027

    		CDK ATM/ATR Cancer
    NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .
    NU6027
  • HY-122038
    NU-8165

    		MDM-2/p53 Cancer
    NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .
    NU-8165
  • HY-116621
    NU-7163

    		DNA-PK Cancer
    NU-7163 is an ATP-competitive DNA-PK inhibitor (IC50=0.19 μM; Ki=24 nM). NU-7163 enhances the cytotoxicity of ionizing radiation against the HeLa human tumor cell line in vitro .
    NU-7163
  • HY-A0149
    Phenindamine

    nu 1504

    		 Histamine Receptor Neurological Disease
    Phenindamine (Nu 1504) is an antihistamine .
    Phenindamine
  • HY-151886
    NU223612

    		PROTACs Indoleamine 2,3-Dioxygenase (IDO) Neurological Disease Cancer
    NU223612 is a potent PROTAC (PROTACs) that degrades indoleamine 2,3-dioxygenase 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO)) with a Kd of 640 nM. NU223612 potently degrades the IDO1 protein through CRBN-mediated proteasomal degradation. NU223612 is bound to CRBN with an affinity of 290 nM. NU223612 can cross the blood-brain barrier (BBB) .
    NU223612
  • HY-145427
    NU5455

    		DNA-PK Cancer
    NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
    NU5455
  • HY-168529
    NU074381b

    		Myosin Cancer
    NU074381b (compound 5b) is a potent S100A4 inhibitor. NU074381b inhibits S100A4-NMII complex formation with an IC50 value of 0.48 µM. NU074381b inhibits cell proliferation and migration .
    NU074381b
  • HY-118379
    NU/ICRF 500

    		Topoisomerase Inflammation/Immunology
    NU/ICRF 500 is a topo II catalytic inhibitor which increases CREST negative micronuclei in human lymphocytes .
    NU/ICRF 500
  • HY-156013
    CA inhibitor 2

    		Carbonic Anhydrase Endocrinology Cancer
    CA inhibitor 2 (Compound 4H) is a carbonic anhydrase inhibitor (IC50: 0.033 μM) .
    CA inhibitor 2
  • HY-15719
    NU 7026
    10+ Cited Publications

    LY293646

    		 DNA-PK Apoptosis Cancer
    NU 7026 (LY293646) is a novel specific DNA-PK inhibitor with IC50 of 0.23 μM, also inhibits PI3K with IC50 of 13 μM.
    NU 7026
  • HY-107419
    NU6140
    1 Publications Verification

    		 CDK Aurora Kinase Cancer
    NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .
    NU6140
  • HY-173066
    NU227326

    		PROTACs Indoleamine 2,3-Dioxygenase (IDO) Cancer
    NU227326 is the PROTAC degrader for Indoleamine 2,3-dioxygenase 1 (IDO1) with DC50 of 4.5 nM. NU227326 degrades IDO1 in cell U87 and GBM43 with DC50 of 7.1 nM and 11.8 nM. NU227326 exhibits good pharmacokinetic properties with a plasma half-life of 5.7 hours and a brain tissue half-life of 11.8 hours .(Pink: ligand for target protein IDO1 ligand-1 (HY-173067); Black: linker (HY-173068); Blue: ligand for E3 ligase Cereblon (HY-W087383))
    NU227326
  • HY-19316
    NU2058

    O6-(Cyclohexylmethyl)guanine

    		 CDK Cancer
    NU2058 (O6-(Cyclohexylmethyl)guanine) is a potent, competitive and guanine-based CDK inhibitor with IC50s of 17 μM and 26 μM for CDK2 and CDK1. NU2058 has anti-cancer activity.
    NU2058
  • HY-15569
    NU6102

    		CDK Cancer
    NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM) .
    NU6102
  • HY-11006
    KU-57788
    30+ Cited Publications

    nu7441

    		 DNA-PK CRISPR/Cas9 Cancer
    KU-57788 (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC50 of 14 nM. KU-57788 is an NHEJ pathway inhibitor. KU-57788 also inhibits PI3K and mTOR with IC50s of 5.0 and 1.7 μM, respectively .
    KU-57788
  • HY-103350
    CA-074
    15+ Cited Publications

    		 Cathepsin Neurological Disease Cancer
    CA-074 is a potent inhibitor of cathepsin B with a Ki of 2 to 5 nM.
    CA-074
  • HY-100350
    CA-074 methyl ester
    25+ Cited Publications

    cA-074Me

    		 Cathepsin Neurological Disease Cancer
    CA-074 methyl ester is a specific inhibitor of Cathepsin B, which has potent bioactivities such as neuroprotective, anti-cancer, and anti-inflamatory effects.
    CA-074 methyl ester
  • HY-162344
    Ir-CA

    		Apoptosis Autophagy Cancer
    Ir-CA is an antitumor agent. Ir-CA can accumulate in mitochondria and induces mitochondria dysfunction. Ir-CA induces apoptosis and autophagy. Ir-CA initiates mitophagy and cell cycle arrest to kill Cisplatin (HY-17394)-resistant A549R cells. Ir-CA can effectively inhibit metastasis by inhibiting MMP-2/MMP-9 .
    Ir-CA
  • HY-W424792A
    O-Desmethyl Brinzolamide hydrochloride

    		Carbonic Anhydrase Drug Metabolite Neurological Disease
    O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonic anhydrase (CA) inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV .
    O-Desmethyl Brinzolamide hydrochloride
  • HY-134923
    CA77.1
    2 Publications Verification

    		 Autophagy Neurological Disease
    CA77.1 is a potent, brain-penetrant and orally active chaperone-mediated autophagy (CMA) activator with favorable pharmacokinetics. CA77.1 is a derivative of AR7 (HY-101106) and can increase the expression of the lysosomal receptor LAMP2A in lysosomes. CA77.1 improves behavior and neuropathology in PS19 mice model and can be used for alzheimer's disease research .
    CA77.1
  • HY-101093
    CA-170
    1 Publications Verification

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .
    CA-170
  • HY-112698
    CA-5f

    		p62 Atg8/LC3 Autophagy Apoptosis Cancer
    CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity .
    CA-5f
  • HY-169209
    CA-M11

    		ATM/ATR Cancer
    CA-M11 (compund CA-M11) can enter the liver area of bile salt transport and release Mirin .
    CA-M11
  • HY-168604
    CA Ⅱ-IN-1

    		Carbonic Anhydrase Cardiovascular Disease
    CA Ⅱ-IN-1 (compound 2i) is a CA Ⅱ isozyme inhibitor, with IC50 of 0.44 µM. CA Ⅱ-IN-1 can be used for metabolic studies .
    CA Ⅱ-IN-1
  • HY-111207
    CA224

    		CDK Apoptosis Cancer
    CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .
    CA224
  • HY-159122
    CA IX-IN-2

    		Carbonic Anhydrase Reactive Oxygen Species Apoptosis Cancer
    CA IX-IN-2 (Compound 9o) is an inhibitor for carbonic anhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC50 of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC50s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .
    CA IX-IN-2
  • HY-146252
    hCAXII-IN-4

    		Carbonic Anhydrase Cancer
    hCAXII-IN-4 (compound 5j) is a potent and selective CA XII inhibitor with an Ki value of 6.4 nM for human CA XII .
    hCAXII-IN-4
  • HY-137459
    Vocacapsaicin

    cA-008

    		 TRP Channel Neurological Disease
    Vocacapsaicin (CA-008), a proagent of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin can provide meaningful and long-lasting pain relief .
    Vocacapsaicin
  • HY-137459A
    Vocacapsaicin hydrochloride

    cA-008 hydrochloride

    		 TRP Channel Neurological Disease
    Vocacapsaicin (CA-008) hydrochloride, a proagent of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin hydrochloride can provide meaningful and long-lasting pain relief .
    Vocacapsaicin hydrochloride
  • HY-168767
    CA IX-IN-3

    		Carbonic Anhydrase Others
    CA IX-IN-3 (Compound 27) is a selective and potent carbonic anhydrase IX (CA IX) inhibitor with an IC50 of 0.48 nM .
    CA IX-IN-3
  • HY-112794
    Topanol CA

    		Others Others
    Topanol CA serves as an effective antioxidant and stabilizer for resins and light-colored rubber products.
    Topanol CA
  • HY-150782
    UNC-CA359

    		EGFR Cancer
    UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC50 value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    UNC-CA359
  • HY-161848
    TCP-MP-CA

    		Histone Demethylase Cancer
    TCP-MP-CA (compound 11a) is an inhibitor of LSD1 demethylation enzymatic via binding to LSD1/CoREST complex. TCP-MP-CA exhibits an inhibitory effect on osteoclastogenesis, with an IC50 value of 0.14 µM .
    TCP-MP-CA
  • HY-149011
    CA IX-IN-1

    		Carbonic Anhydrase Cancer
    CA IX-IN-1 (compound 12g) is an effective and selective inhibitor of hCA IX with IC50 value of 7 nM. CA IX-IN-1 exhibits antitumor activity .
    CA IX-IN-1
  • HY-B1558
    Bifemelane

    MCI-2016 free base

    		 Calcium Channel Neurological Disease
    Bifemelane is a nootropic compound. Bifemelan causes the first peak by stimulating release from intracellular Ca 2+ stores and the second by capacitive entry through store–operated Ca 2+ channels. Bifemelane will be provided as a pharmacological tool for basic studies on astrocytes .
    Bifemelane
  • HY-163380
    CA/MAO-B-IN-1

    		Carbonic Anhydrase Neurological Disease
    CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .
    CA/MAO-B-IN-1
  • HY-123237
    KRC-108

    		c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy Cancer
    KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .
    KRC-108
  • HY-P10811
    Na2+ - Ca2+ Exchanger inhibitory peptide

    XIP

    		 Na+/Ca2+ Exchanger Neurological Disease
    Na +-Ca 2+ Exchanger inhibitory peptide (XIP) is a Na +-Ca 2+ exchanger inhibitor with a Ki of 200 nM. Na +-Ca 2+ Exchanger inhibitory peptide inhibits the Na +-dependent Ca 2+ uptake and the Na +-dependent Ca 2+ efflux of sarcolemmal vesicles in a noncompetitive manner .
    Na2+ - Ca2+ Exchanger inhibitory peptide
  • HY-158328A
    CA IX/VEGFR-2-IN-2

    		Carbonic Anhydrase VEGFR Reactive Oxygen Species MDM-2/p53 Bcl-2 Family Cytochrome P450 Caspase Cancer
    CA IX/VEGFR-2-IN-2 (compound 5e) is a dual-targeted inhibitor. CA IX/VEGFR-2-IN-2 shows strong inhibitory effects on both CA IX (Ki=3.1 μM) and VEGFR-2 (IC50=32.1 nM). CA IX/VEGFR-2-IN-2 can be used for the study of pancreatic (PANC1), breast cancer (MCF7) and prostate cancer (PC3) .
    CA IX/VEGFR-2-IN-2
  • HY-168603
    AChE/CA I-IN-1

    		Cholinesterase (ChE) Carbonic Anhydrase Neurological Disease
    AChE/CA I-IN-1 (Compound 2g) is the inhibitor for AChE and hCA I with Ki of 1.85 and 0.53 µM. AChE/CA I-IN-1 exhibits potential application in researches about Alzheimer's disease, glaucoma, and epilepsy .
    AChE/CA I-IN-1
  • HY-17404
    Cilnidipine
    1 Publications Verification

    FRC-8653

    		 Calcium Channel Cardiovascular Disease
    Cilnidipine is a long-acting, second-generation dihydropyridine Ca 2+-channel blocker on L and N-type Ca 2+ channel . Antihypertensive effects .
    Cilnidipine
  • HY-135317F
    Emavusertib phosphate

    cA-4948 phosphate

    		 IRAK FLT3 NF-κB MyD88 Apoptosis Inflammation/Immunology Cancer
    Emavusertib phosphate (CA-4948 phosphate) is the phosphate salt form of Emavusertib (HY-135317). Emavusertib phosphate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib phosphate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib phosphate exhibits antitumor activity in mouse model .
    Emavusertib phosphate
  • HY-135317E
    Emavusertib maleate

    cA-4948 maleate

    		 IRAK FLT3 NF-κB MyD88 Apoptosis Inflammation/Immunology Cancer
    Emavusertib maleate (CA-4948 maleate) is the maleate salt form of Emavusertib (HY-135317). Emavusertib maleate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib maleate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib maleate exhibits antitumor activity in mouse model .
    Emavusertib maleate
  • HY-135317C
    Emavusertib tosylate

    cA-4948 tosylate

    		 IRAK FLT3 NF-κB MyD88 Apoptosis Inflammation/Immunology Cancer
    Emavusertib tosylate (CA-4948 tosylate) is the tosylate salt form of Emavusertib (HY-135317). Emavusertib tosylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib tosylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib tosylate exhibits antitumor activity in mouse model .
    Emavusertib tosylate
  • HY-135317B
    Emavusertib hydrochloride

    cA-4948 hydrochloride

    		 IRAK FLT3 Apoptosis NF-κB MyD88 Inflammation/Immunology Cancer
    Emavusertib hydrochloride (CA-4948 tosylate) is the hydrochloride salt form of Emavusertib (HY-135317). Emavusertib hydrochloride is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib hydrochloride inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib hydrochloride exhibits antitumor activity in mouse model .
    Emavusertib hydrochloride
  • HY-135317D
    Emavusertib mesylate

    cA-4948 mesylate

    		 IRAK FLT3 NF-κB MyD88 Apoptosis Inflammation/Immunology Cancer
    Emavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib (HY-135317). Emavusertib mesylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib mesylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib mesylate exhibits antitumor activity in mouse model .
    Emavusertib mesylate
  • HY-W749867
    Ca(II)-EDTA disodium dihydrate

    cAlcium disodium EDTA dihydrate

    		 Bacterial Infection Others
    CaⅡ-EDTA disodium dihydrate (Calcium disodium EDTA dihydrate) is an orally active metal chelating reagent, exhibits bactericidal activities against periodontal pathogens Aggregatibacter actinomycetemcomitans, Prevotella intermedia and Porphyromonas gingivalis . CaⅡ-EDTA disodium dihydrate is effective chelating antidotes for lead- and cadmium poisoning .
    Ca(II)-EDTA disodium dihydrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: